{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:15:05Z","timestamp":1788308105492,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024073","name":"Dr. Willmar Schwabe GmbH & Co. KG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024073","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Major depressive disorder (MDD) is characterized by depressed mood, anhedonia, and loss of energy, which can be accompanied by associated symptoms and co-morbidities. Psychiatric scales such as the Montgomery \u00c5sberg Depression Rating Scale (MADRS) must account for the complex nature of depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The MADRS total score change between baseline and week 8 was the primary outcome measure in a randomized, double-blind clinical trial investigating the antidepressant efficacy of 8\u00a0weeks\u2019 treatment with silexan compared to sertraline and placebo in patients with mild or moderate MDD. We report on a pre-planned, exploratory analysis of the individual MADRS items. Treatment effects were assessed using analyses of covariance with baseline adjustment, based on an estimand strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>498 subjects (silexan 170, sertraline 171, placebo 157) were treated and analyzed. After 8\u00a0weeks, silexan was superior to placebo for 5 out of the 9 MADRS items analyzed (\u201capparent sadness\u201d, \u201creported sadness\u201d, \u201creduced appetite\u201d, \u201cconcentration difficulties\u201d, \u201classitude\u201d; P\u00a0&amp;lt;\u2009.05) and showed clinically important adjusted mean value differences &amp;gt;0.2 points for 7 out of the 9 items. Item-level results for silexan and sertraline were mainly comparable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Silexan had a strong over-all antidepressant effect, with the most pronounced improvements affecting the cardinal symptoms of depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EudraCT2020-000688-22 first entered on 12\/08\/2020.<\/jats:p>\n                    <jats:p>Significance statement Patients with depressive disorders can show many different symptoms. To better characterize the clinical action of an antidepressant, it is therefore important to analyze not only the overall value of a depression scale but also the individual items that describe these symptoms. Silexan is a preparation from lavender oil whose antidepressant effect has been proven in a randomized, double-blind, placebo-controlled 8-week study in patients with mild or moderate major depressive disorder. Based on the individual items of the Montgomery \u00c5sberg Depression Rating Scale that was used as the main outcome for efficacy, we found in an exploratory, hypothesis-generating analysis that silexan had a rather broad antidepressant effect in the participants of our study, with potentially clinically meaningful advantages over placebo for 7 out of the 9 individual items investigated. This applied in particular to the main symptoms of depression, namely sadness and lassitude. Our single-item analysis thus helps to understand the antidepressant effects of silexan in more detail. Significant outcomes In patients with mild to moderate major depressive disorder, lavender oil preparation silexan has a clinical profile similar to that of the selective serotonin re-uptake inhibitor sertraline based on an item-level analysis of the Montgomery-\u00c5sberg Depression Rating Scale (MADRS). Silexan has a significant antidepressant effect that includes an alleviation of depressed mood, anhedonia, and loss of energy, the cardinal symptoms of depression. The broad improvement of symptoms of depression could not be explained by the proven anxiolytic efficacy silexan alone but indicates an independent, direct antidepressant effect. The present item-level analysis provides valuable and detailed additional insights into the therapeutic profiles of silexan and sertraline and may help clinicians to tailor antidepressant treatment to the specific symptoms of a patient. Limitations For item-level analyses of the MADRS, no validated thresholds for the assessment of the clinical importance of changes over time have been defined, taking into account that different items may have different thresholds. Even though our analyses were pre-defined, they were exploratory and did not include studywise type I error level control. Their generalizability beyond the study population is therefore limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyag041","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:06:45Z","timestamp":1785586005000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of lavender oil preparation silexan on different symptoms of major depression \u2013 results from a randomized, controlled trial"],"prefix":"10.1093","volume":"29","author":[{"given":"Hans-J\u00fcrgen","family":"M\u00f6ller","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Ludwig Maximilian University , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion-George","family":"Anghelescu","sequence":"additional","affiliation":[{"name":"Clinic of Psychiatry and Psychotherapy, Mental Health Institute Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-8918","authenticated-orcid":false,"given":"Hans-Peter","family":"Volz","sequence":"additional","affiliation":[{"name":"Former Medical Director Hospital for Psychiatry, Psychotherapy and Psychosomatic Medicine Schloss Werneck , Werneck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Z\u00fcrich , Munich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schl\u00e4fke","sequence":"additional","affiliation":[{"name":"Research & Development, Dr. Willmar Schwabe GmbH & Co. KG , Karlsruhe ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-191X","authenticated-orcid":false,"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Ludwig Maximilian University , Munich ,","place":["Germany"]},{"name":"Center for Brain Research, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026090119362127700_ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, DSM-5","author":"American Psychiatric Association","year":"2013","edition":"5th Edition"},{"key":"2026090119362127700_ref2","volume-title":"ICD-11: International Classification of Diseases","author":"World Health Organization","year":"2019","edition":"11th revision"},{"key":"2026090119362127700_ref3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2026090119362127700_ref4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br J Soc Clin Psychol"},{"key":"2026090119362127700_ref5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1600-0447.1986.tb02723.x","article-title":"The Montgomery-Asberg depression scale: reliability and validity","volume":"73","author":"Davidson","year":"1986","journal-title":"Acta Psychiatr Scand"},{"key":"2026090119362127700_ref6","doi-asserted-by":"publisher","first-page":"1289630","DOI":"10.3389\/fpsyt.2024.1289630","article-title":"A qualitative investigation of the Montgomery-\u00c5sberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression","volume":"15","author":"Capodilupo","year":"2024","journal-title":"Front Psychiatry"},{"key":"2026090119362127700_ref7","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00406-021-01301-8","article-title":"A symptom-based approach in predicting ECT outcome in depressed patients employing MADRS single items","volume":"271","author":"Carstens","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2026090119362127700_ref8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jpsychires.2009.02.001","article-title":"Sensitivity of the Montgomery Asberg depression rating scale to response and its consequences for the assessment of efficacy","volume":"43","author":"Santen","year":"2009","journal-title":"J Psychiatr Res"},{"key":"2026090119362127700_ref9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/mpr.1388","article-title":"The structure of the Montgomery-\u00c5sberg depression rating scale over the course of treatment for depression","volume":"22","author":"Quilty","year":"2013","journal-title":"Int J Methods Psychiatr Res"},{"key":"2026090119362127700_ref10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12888-023-05038-7","article-title":"A factor analytic comparison of three commonly used depression scales (HAMD, MADRS, BDI) in a large sample of depressed inpatients","volume":"23","author":"Seem\u00fcller","year":"2023","journal-title":"BMC Psychiatry"},{"key":"2026090119362127700_ref11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jad.2006.02.011","article-title":"Clinical relevance of depressive symptom improvement in bipolar I depressed patients","volume":"92","author":"Williamson","year":"2006","journal-title":"J Affect Disord"},{"key":"2026090119362127700_ref12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40263-022-00916-2","article-title":"Evaluation of individual items of the patient health questionnaire (PHQ-9) and Montgomery-Asberg depression rating scale (MADRS) in adults with treatment-resistant depression treated with Esketamine nasal spray combined with a new oral antidepressant","volume":"36","author":"Floden","year":"2022","journal-title":"CNS Drugs"},{"key":"2026090119362127700_ref13","doi-asserted-by":"publisher","first-page":"102904","DOI":"10.1016\/j.eclinm.2024.102904","article-title":"Impact of sedative and appetite-increasing properties on the apparent antidepressant efficacy of mirtazapine, selective serotonin reuptake inhibitors and amitriptyline: an item-based, patient-level meta-analysis","volume":"77","author":"Hieronymus","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026090119362127700_ref14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41386-019-0523-4","article-title":"Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study","volume":"45","author":"Lisinski","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"2026090119362127700_ref15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/wps.20630","article-title":"The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis","volume":"18","author":"Boschloo","year":"2019","journal-title":"World Psychiatry"},{"key":"2026090119362127700_ref16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00406-022-01390-z","article-title":"Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited","volume":"273","author":"Bartova","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2026090119362127700_ref17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.euroneuro.2015.12.002","article-title":"Efficacy of Silexan in mixed anxiety-depression - a randomized, placebo-controlled trial","volume":"26","author":"Kasper","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026090119362127700_ref18","volume-title":"International Statistical Classification of Diseases and Related Health Porblems, Tenth Revision (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"2026090119362127700_ref19","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00406-024-01783-2","article-title":"Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial","volume":"275","author":"Kasper","year":"2024","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2026090119362127700_ref20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/acps.12801","article-title":"From depression to anxiety, and back","volume":"136","author":"Bui","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"2026090119362127700_ref21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/da.23113","article-title":"Co-morbidity between mood and anxiety disorders: a systematic review and meta-analysis","volume":"38","author":"Saha","year":"2021","journal-title":"Depress Anxiety"},{"key":"2026090119362127700_ref22","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1017\/S0033291716002300","article-title":"Network analysis of depression and anxiety symptom relationships in a psychiatric sample","volume":"46","author":"Beard","year":"2016","journal-title":"Psychol Med"},{"key":"2026090119362127700_ref23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41398-022-02157-9","article-title":"Pathological fear, anxiety and negative affect exhibit distinct neurostructural signatures: evidence from psychiatric neuroimaging meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Transl Psychiatry"},{"key":"2026090119362127700_ref24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/15622975.2022.2086295","article-title":"World Federation of Societies of biological psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders \u2013 version 3. Part I: anxiety disorders","volume":"24","author":"Bandelow","year":"2023","journal-title":"World J Biol Psychiatry"},{"key":"2026090119362127700_ref25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/a-1293-8585","article-title":"Neurotrophic properties of Silexan, an essential oil from the flowers of lavender-preclinical evidence for antidepressant-like properties","volume":"54","author":"Friedland","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"2026090119362127700_ref26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neulet.2019.02.042","article-title":"Lavender essential oil ameliorates depression-like behavior and increases neurogenesis and dendritic complexity in rats","volume":"701","author":"S\u00e1nchez-Vida\u00f1a","year":"2019","journal-title":"Neurosci Lett"},{"key":"2026090119362127700_ref27","doi-asserted-by":"publisher","first-page":"104899","DOI":"10.1016\/j.neuint.2020.104899","article-title":"Pharmacological basis of the anxiolytic and antidepressant properties of Silexan(R), an essential oil from the flowers of lavender","volume":"143","author":"M\u00fcller","year":"2021","journal-title":"Neurochem Int"},{"key":"2026090119362127700_ref28","article-title":"Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging","volume":"18","author":"Baldinger","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026090119362127700_ref29","doi-asserted-by":"publisher","first-page":"P654","DOI":"10.1055\/s-0030-1264952","article-title":"Effects of intraperitoneal administration of Silexan, an essential oil from flowers of Lavandula angustifolia on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex of freely moving rats","volume":"76","author":"Kehr","year":"2010","journal-title":"Planta Med"},{"key":"2026090119362127700_ref30","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00406-024-01923-8","article-title":"Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data","volume":"275","author":"Kasper","year":"2024","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2026090119362127700_ref31","doi-asserted-by":"publisher","DOI":"10.4324\/9780203308356","volume-title":"Assessment Scales in Depression, Mania and Anxiety","author":"Lam","year":"2005"},{"key":"2026090119362127700_ref32","volume-title":"European Pharmacopoeia","author":"Council of Europe","year":"2022","edition":"11th"},{"key":"2026090119362127700_ref33","volume-title":"Guideline on Clinical Investigation of Medicinal Products in the Treatment of Depression. Revision 3","author":"Committee for Medicinal Products for Human Use","year":"2025"},{"key":"2026090119362127700_ref34","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1459.1000182","article-title":"Interpretation of statistical significance - exploratory versus confirmative testing in clinical trials, epidemiological studies, meta-analyses and toxicological screening (using Ginkgo biloba as an example)","volume":"05","author":"Gaus","year":"2015","journal-title":"Clin Exp Pharmacol"},{"key":"2026090119362127700_ref35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1037\/gpr0000123","article-title":"Do p values lose their meaning in exploratory analyses? It depends how you define the familywise error rate","volume":"21","author":"Rubin","year":"2017","journal-title":"Rev Gen Psychol"},{"key":"2026090119362127700_ref36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/15622975.2021.2013092","article-title":"Effect of anxiolytic drug silexan on sleep - a narrative review","volume":"23","author":"Seifritz","year":"2022","journal-title":"World J Biol Psychiatry"},{"key":"2026090119362127700_ref37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ijnp\/pyaa064","article-title":"No abuse potential of Silexan in healthy recreational drug users: a randomized controlled trial","volume":"24","author":"Seifritz","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026090119362127700_ref38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11920-017-0816-4","article-title":"Effects of antidepressants on sleep","volume":"19","author":"Wichniak","year":"2017","journal-title":"Curr Psychiatry Rep"},{"key":"2026090119362127700_ref39","doi-asserted-by":"publisher","first-page":"e1927","DOI":"10.1002\/mpr.1927","article-title":"Montgomery-\u00c5sberg depression rating scale factors in treatment-resistant depression at onset of treatment: derivation, replication, and change over time during treatment with esketamine","volume":"31","author":"Borentain","year":"2022","journal-title":"Int J Meth Psychiatr Res"},{"key":"2026090119362127700_ref40","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1185\/030079908X291958","article-title":"The clinical relevance of changes in the Montgomery-Asberg depression rating scale using the minimum clinically important difference approach","volume":"24","author":"Duru","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2026090119362127700_ref41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","article-title":"Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"2026090119362127700_ref42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/YIC.0b013e32833b3242","article-title":"Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial","volume":"25","author":"Kasper","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"2026090119362127700_ref43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jpsychires.2019.04.013","article-title":"Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect","volume":"115","author":"Seifritz","year":"2019","journal-title":"J Psychiatr Res"},{"key":"2026090119362127700_ref44","doi-asserted-by":"publisher","first-page":"1491451","DOI":"10.3389\/fpsyt.2024.1491451","article-title":"MADRS single items differential changes among patients with melancholic and unspecified depression treated with ECT: an exploratory study","volume":"15","author":"Pozuelo Moyano","year":"2024","journal-title":"Front Psychiatry"},{"key":"2026090119362127700_ref45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ijnp\/pyy009","article-title":"Major depression and the degree of suicidality: results of the European Group for the Study of resistant depression (GSRD)","volume":"21","author":"Dold","year":"2018","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyag041\/70480866\/pyag041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/9\/pyag041\/70480866\/pyag041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/9\/pyag041\/70480866\/pyag041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:36:27Z","timestamp":1788305787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyag041\/8751140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyag041","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"pyag041"}}